Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4567207 | 1.00 | CYP19A1 (0.36) | CYP19A1PRKCAFAAHCNR1CNR2 | |
| SCHEMBL4567206 | 0.89 | CYP19A1 (0.34) | CYP19A1PRKCAMMP1MMP2MMP3 | |
| SCHEMBL26517483 | 0.88 | MGAM (0.35) | CYP19A1FAAHCNR1CNR2 | |
| SCHEMBL26517478 | 0.88 | MGAM (0.35) | CYP19A1FAAHCNR1CNR2 | |
| SCHEMBL25626538 | 0.86 | — | — | |
| SCHEMBL25465036 | 0.85 | CYP19A1 (0.36) | CYP19A1PRKCAMMP1MMP2MMP3 | |
| SCHEMBL22205224 | 0.84 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL22205226 | 0.84 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL21974553 | 0.84 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL16053327 | 0.84 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890264-B2 | Migraine prevention and treatment | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2024-02-06 | — | — | US | claimed |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2021-11-04 | — | — | US | claimed |
| US-20250275986-A1 | COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT | KETOSWISS AG (CH) | 2025-09-04 | — | — | US | disclosed |
| US-12396974-B2 | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections | KetoneAid (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250234904-A1 | KETONE BEVERAGE CONTAINING CAFFEINE AND (R)-1,3-BUTANEDIOL AND/OR (R)-BETA-HYDROXYBUTYRIC ACID AND SALTS | KETONEAID, INC | 2025-07-24 | — | — | US | disclosed |
| EP-4373483-A1 | COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT | KetoSwiss AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| US-20240074459-A1 | KETONE BEVERAGE CONTAINING A SLOW CARBOHYDRATE | KETONEAID, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11890264-B2 | Migraine prevention and treatment | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2024-02-06 | — | — | US | disclosed |
| US-11786499-B2 | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function | AXCESS GLOBAL SCIENCES, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786499-B2 | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function | AXCESS GLOBAL SCIENCES, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4245368-A2 | MIGRAINE PREVENTION AND TREATMENT | Universitäts-kinderspital Beider Basel (CH) | 2023-09-20 | — | — | EP | disclosed |
| US-11202769-B2 | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function | AXCESS GLOBAL SCIENCES, LLC (US) | 2021-12-21 | — | — | US | disclosed |
| US-11166928-B2 | Migraine prevention and treatment | UNIVERSITATS-KINDERSPITAL BEIDER BASEL | 2021-11-09 | — | — | US | disclosed |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2021-11-04 | — | — | US | disclosed |
| WO-2021195477-A1 | KETONE ESTER AS A THERAPEUTIC TREATMENT OF COVID-19, LONG COVID, AND RELATED VIRAL INFECTIONS | KETONEAID, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195477-A1 | KETONE ESTER AS A THERAPEUTIC TREATMENT OF COVID-19, LONG COVID, AND RELATED VIRAL INFECTIONS | KETONEAID, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210169831-A1 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION | AXCESS GLOBAL SCIENCES, LLC | 2021-06-10 | — | — | US | disclosed |
| EP-3558280-A1 | MIGRAINE PREVENTION AND TREATMENT | Universitäts-kinderspital Beider Basel (CH) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115158-A1 | MIGRAINE PREVENTION AND TREATMENT | UNIVERSITÄTS-KINDERSPITAL BEIDER BASEL (CH) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786499-B2 | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function | HADHB, BCKDK, CPT1B | CYP19A1 1169/4885PRKCA 1260/4885FAAH 538/4885 |
| US-11202769-B2 | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function | HADHB, BCKDK, CPT1B | CYP19A1 1169/4885PRKCA 1260/4885FAAH 538/4885 |
| US-20210169831-A1 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION | HADHB, BCKDK, CPT1B | CYP19A1 1169/4885PRKCA 1260/4885FAAH 538/4885 |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | ACACA, ACACB, HBB | CYP19A1 1327/4885PRKCA 1583/4885FAAH 12/4885 |
| US-11166928-B2 | Migraine prevention and treatment | ACACA, ACACB, HBB | CYP19A1 1327/4885PRKCA 1583/4885FAAH 12/4885 |
| US-12396974-B2 | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections | ACE, HSD17B13, IL1B | CYP19A1 2315/4885PRKCA 546/4885FAAH 47/4885 |
| US-11890264-B2 | Migraine prevention and treatment | ACACA, ACACB, HBB | CYP19A1 1327/4885PRKCA 1583/4885FAAH 12/4885 |
| US-20250275986-A1 | COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT | PKM, KCNMA1, KCNK18 | CYP19A1 654/4885PRKCA 565/4885FAAH 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.